Current sickle cell disease (SCD) trial eligibility criteria exclude most adults, with only 9.9% meeting inclusion thresholds ...
Historically characterized by excessive daytime sleepiness and cataplexy, narcolepsy is increasingly recognized as a ...
Phase 1 BALLI-01 trial results showed promising UCART22 activity in R/R B-cell ALL, with higher remission rates after a ...
Tebipenem pivoxil becomes the only FDA-approved oral carbapenem for complicated UTIs/pyelonephritis in adults lacking viable ...
First, the AASM guideline recommends a combination of CBT‑I and medication over medication alone for adults with chronic ...
Standardized order sets, clinical team training on toxicity grading and treatment algorithms, and immediate access to ...
Prolonged follow-up showed superior PFS with mosun-pola versus R-GemOx in the overall SUNMO population (HR, 0.41) alongside ...
Alexander Spira, MD, PhD, medical oncologist at Virginia Cancer Specialists and chief scientific officer of NEXT Oncology, ...
EHA 2026 highlights included practice-changing immunotherapy data in relapsed/refractory multiple myeloma and high-risk pediatric B-cell ALL, plus insights on childhood cancer predisposition.
Walcker will oversee enterprise strategy, operations, and growth at The Specialty Alliance, while James Weber, MD, focuses on ...
Maintenance revumenib was restarted post SCT at the pretransplant dose with azole-based adjustments across monotherapy, combination-trial, and expanded-access settings in genetically defined ...
This analysis compared health care resource utilization and costs for Medicaid patients with serious mental illness between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results